SPRO — Spero Therapeutics Inc · P/E 9.6, rev $258.0K

Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.

Latest reported SPRO revenue for 2026-06-30 was $258.0K. Net income was -$16.8M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.

Use this SPRO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SPRO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SPRO SEC filings page. Lician reads the product cache first so this HTML stays unique to Spero Therapeutics Inc even when a live quote feed is slow.

Spero Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full SPRO income, balance, and cash tables.

  • Revenue$66.8M
  • Net Income$8.6M
  • Total Assets$68.9M
  • Total Debt$0
  • Free Cash Flow$0

SPRO recent filings